AI assistant
bioAffinity Technologies, Inc. — Director's Dealing 2022
Nov 22, 2022
35439_dirs_2022-11-22_34472c87-e612-476a-9382-bc80467444c5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2022-08-29
Reporting Person: Rebel Vivienne I (EVP, Chief Sci. & Med. Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, par value $0.007 | 7142 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $7.00 | 2026-07-25 | Common Stock (2857) | Direct | |
| Stock Option (right to buy) | $7.70 | 2027-11-20 | Common Stock (2857) | Direct | |
| Stock Option (right to buy) | $7.70 | 2029-02-25 | Common Stock (4285) | Direct | |
| Stock Option (right to buy) | $7.70 | 2030-02-05 | Common Stock (4285) | Direct |
Footnotes
F1: The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering.
F2: Represents a right to purchase 2,857 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the Issuer's 2014 Equity Incentive Plan (the "EIP") on July 25, 2016. This option vested in 12 monthly installments beginning on August 25, 2016 and is fully vested and exercisable as of the date of this report.
F3: Represents a right to purchase 2,857 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on November 20, 2017. This option vested in 12 monthly installments beginning on December 20, 2017 and is fully vested and exercisable as of the date of this report.
F4: Represents a right to purchase 4,285 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on February 25, 2019. This option vested in 12 monthly installments beginning on March 25, 2019 and is fully vested and exercisable as of the date of this report.
F5: Represents a right to purchase 4,285 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on February 5, 2020. This option vested in 12 monthly installments beginning on March 5, 2020 and is fully vested and exercisable as of the date of this report.